Constellation: A tool for rapid, automated phenotype assignment of a highly polymorphic pharmacogene, CYP2D6, from whole-genome sequences

npj Genomic Medicine

Volumn 1, Issue , 2016, Pages

  Twist, Greyson P ^a,b   Gaedigk, Andrea ^c,d,e   Miller, Neil A ^a,g   Farrow, Emily G ^a,e   Willig, Laurel K ^a,d,e   Dinwiddie, Darrell L ^f   Petrikin, Josh E ^a,d,e   Soden, Sarah E ^a,d,e   Herd, Suzanne ^a   Gibson, Margaret ^a   Cakici, Julie A ^a   Riffel, Amanda K ^c   Leeder, J Steven ^a,c,d,e   Dinakarpandian, Deendayal ^b,e   Kingsmore, Stephen F ^a,d,e,g  

^a Center for Pediatric Genomic Medicine   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c Division of Clinical Pharmacology   (United States)

^d Rady Children's Hospital ^*  (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^g RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85009182671     PISSN: None     EISSN: 20567944     Source Type: Journal    
DOI: 10.1038/npjgenmed.2015.7     Document Type: Article

References (49)

1. Zhou, S. F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet. 48, 689-723 (2009).
2. Zhou, S. F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin. Pharmacokinet. 48, 761-804 (2009).
3. Sim, S. C. & Ingelman-Sundberg, M. Update on Allele Nomenclature for Human Cytochromes P450 and the Human Cytochrome P450 Allele (CYP-Allele) Nomenclature Database. Methods Mol. Biol. 987, 251-259 (2013).
4. Koren, G., Cairns, J., Chitayat, D., Gaedigk, A. & Leeder, S. J. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368, 704 (2006).
5. Prows, C. A. et al. Codeine-related adverse drug reactions in children following tonsillectomy: A prospective study. Laryngoscope 124, 1242-1250 (2014).
6. Haufroid, V. & Hantson, P. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants. Clin. Toxicol. 53, 501-510 (2015).
7. Gasso, P. et al. Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. Pharmacogenomics J. 14, 457-462 (2014).
8. Zhou, Z. W. et al. Clinical association between pharmacogenomics and adverse drug reactions. Drugs 75, 589-631 (2015).
9. Crews, K. R. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update. Clin. Pharmacol. Ther. 95, 376-382 (2014).
10. Hicks, J. K. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin. Pharmacol. Ther. 98, 127-134 (2015).
11. Hicks, J. K. et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants. Clin. Pharmacol. Ther. 93, 402-408 (2013).
12. Swen, J. J. et al. Pharmacogenetics: from bench to byte-An update of guidelines. Clin. Pharmacol. Ther. 89, 662-673 (2011).
13. Kimura, S., Umeno, M., Skoda, R. C., Meyer, U. A. & Gonzalez, F. J. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am. J. Hum. Genet. 45, 889-904 (1989).
14. Gaedigk, A. Complexities of CYP2D6 gene analysis and interpretation. Int. Rev. Psychiatry 25, 534-553 (2013).
15. Hicks, J. K., Swen, J. J. & Gaedigk, A. Challenges in CYP2D6 phenotype assignment from genotype data: A critical assessment and call for standardization. Curr. Drug Metab. 15, 218-232 (2014).
16. Drögemöller, B. I., Wright, G. E., Niehaus, D. J., Emsley, R. & Warnich, L. Nextgeneration sequencing of pharmacogenes: A critical analysis focusing on schizophrenia treatment. Pharmacogenet. Genomics 23, 666-674 (2013).
17. Bainbridge, M. N. et al. Whole-genome sequencing for optimized patient management. Sci. Transl. Med. 3, 87re83 (2011).
18. Kingsmore, S. F. & Saunders, C. J. Deep sequencing of patient genomes for disease diagnosis: When will it become routine? Sci. Transl. Med. 3, 87ps23 (2011).
19. Saunders, C. J. et al. Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units. Sci. Transl. Med. 4, 154ra135 (2012).
20. Soden, S. E. et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. Sci. Transl. Med. 6, 265ra168 (2014).
21. Grove, M. E., Wolpert, M. N., Cho, M. K., Lee, S. S. & Ormond, K. E. Views of genetics health professionals on the return of genomic results. J. Genet. Counsel. 23, 531-538 (2014).
22. Nishimura, A. A. et al. Development of clinical decision support alerts for pharmacogenomic incidental findings from exome sequencing. Genet. Med. 17, 939-942 (2015).
23. Dancik, V., Addona, T. A., Clauser, K. R., Vath, J. E. & Pevzner, P. A. De novo peptide sequencing via tandem mass spectrometry. J. Comput. Biol. 6, 327-342 (1999).
24. Jaccard, P. Étude comparative de la distribution florale dans une portion des Alpes et des Jura. Bulletin de la Société Vaudoise des Sciences Naturelles 37, 547-579 (1901).
25. Zook, J. M. et al. Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls. Nat. Biotechnol. 32, 246-251 (2014).
26. Montane Jaime, L. K., Lalla, A., Steimer, W. & Gaedigk, A. Characterization of the CYP2D6 gene locus and metabolic activity in Indo-And Afro-Trinidadians: discovery of novel allelic variants. Pharmacogenomics 14, 261-276 (2013).
27. Probst-Schendzielorz, K., Viviani, R. & Stingl, J. C. Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors. Expert Opin. Drug Metab. Toxicol. 11, 1219-1232 (2015).
28. Fitzgerald, T. W. et al. Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. Nature 519, 223-228 (2015).
29. Wright, C. F. et al. Genetic diagnosis of developmental disorders in the DDD study: A scalable analysis of genome-wide research data. Lancet 385, 1305-1314 (2015).
30. Whirl-Carrillo, M. et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92, 414-417 (2012).
31. Botkin, J. R. et al. Points to consider: Ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am. J. Hum. Genet. 97, 6-21 (2015).
32. Beitelshees, A. L., Voora, D. & Lewis, J. P. Personalized antiplatelet and anticoagulation therapy: Applications and significance of pharmacogenomics. Pharmacogenomics and Pers. Med. 8, 43-61 (2015).
33. Muller, D. J., Kekin, I., Kao, A. C. & Brandl, E. J. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. Int. Rev. Psychiatry 25, 554-571 (2013).
34. Leeder, J. S., Brown, J. T. & Soden, S. E. Individualizing the use of medications in children: making Goldilocks happy. Clin. Pharmacol. Ther. 96, 304-306 (2014).
35. Kalman, L. V. et al. Pharmacogenetic allele nomenclature: international workgroup recommendations for test result reporting. Clin. Pharmacol. Ther. e-pub ahead of print 19 October 2015; doi:10.1002/cpt.280.
36. Numanagic, I. et al. Cypiripi: Exact genotyping of CYP2D6 using high-Throughput sequencing data. Bioinformatics 31, i27-i34 (2015).
37. Gaedigk, A., Twist, G. P. & Leeder, J. S. CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR. Pharmacogenomics 13, 91-111 (2012).
38. Fujikura, K., Ingelman-Sundberg, M. & Lauschke, V. M. Genetic variation in the human cytochrome P450 supergene family. Pharmacogenet. Genomics 25, 584-594 (2015).
39. Gaedigk, A. et al. Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J. 5, 173-182 (2005).
40. Gaedigk, A., Bradford, L. D., Alander, S. W. & Leeder, J. S. CYP2D6∗36 gene arrangements within the CYP2D6 locus: Association of CYP2D6∗36 with poor metabolizer status. Drug. Metab. Dispos. 34, 563-569 (2006).
41. Gaedigk, A. et al. CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics 11, 43-53 (2010).
42. Gaedigk, A. et al. Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants. Front. Pharmacol. 1, 121 (2010).
43. Gaedigk, A. et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin. Pharmacol. Ther. 81, 242-251 (2007).
44. Gaedigk, A. et al. The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83, 234-242 (2008).
45. Sim, S. C., Daly, A. K. & Gaedigk, A. CYP2D6 update: Revised nomenclature for CYP2D7/2D6 hybrid genes. Pharmacogenet. Genomics 22, 692-694 (2012).
46. Gaedigk, A., Riffel, A. K. & Leeder, J. S. CYP2D6 haplotype determination using long range allele-specific PCR amplification: Resolution of a complex genotype and a discordant genotype involving the CYP2D6∗59 allele. J. Mol. Diagn. 17, 740-748 (2015).
47. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491-498 (2011).
48. Wu, T. D. & Nacu, S. Fast and SNP-Tolerant detection of complex variants and splicing in short reads. Bioinformatics 26, 873-881 (2010).
49. McKenna, A. et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).